drug
vibegron
Marketedupdated 3mo agoby Sumitomo Pharma America Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
Trials studying vibegron
- —Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
- phase3Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
- phase3Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
- phase3A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 18, 2027
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Jul 6, 2042method-of-use (U-4219)US 12357636
- Mar 22, 2040method-of-use (U-3045)US 12102638
- Dec 23, 2034compositionUS 8247415
- Mar 12, 2034compositionUS 12180219
- Apr 2, 2029compositionUS 86532602.6y
FDA exclusivities (1)
- Dec 18, 2027I-955Indication (3y)1.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that